Nature Communications (Sep 2023)

MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer

  • Zinab O. Doha,
  • Xiaoyan Wang,
  • Nicholas L. Calistri,
  • Jennifer Eng,
  • Colin J. Daniel,
  • Luke Ternes,
  • Eun Na Kim,
  • Carl Pelz,
  • Michael Munks,
  • Courtney Betts,
  • Sunjong Kwon,
  • Elmar Bucher,
  • Xi Li,
  • Trent Waugh,
  • Zuzana Tatarova,
  • Dylan Blumberg,
  • Aaron Ko,
  • Nell Kirchberger,
  • Jennifer A. Pietenpol,
  • Melinda E. Sanders,
  • Ellen M. Langer,
  • Mu-Shui Dai,
  • Gordon Mills,
  • Koei Chin,
  • Young Hwan Chang,
  • Lisa M. Coussens,
  • Joe W. Gray,
  • Laura M. Heiser,
  • Rosalie C. Sears

DOI
https://doi.org/10.1038/s41467-023-40841-6
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new therapies, however, few mouse models represent the complexity of TNBC. Here, we develop a female TNBC murine model by mimicking two common TNBC mutations with high co-occurrence: amplification of the oncogene MYC and deletion of the tumor suppressor PTEN. This Myc;Ptenfl model develops heterogeneous triple-negative mammary tumors that display histological and molecular features commonly found in human TNBC. Our research involves deep molecular and spatial analyses on Myc;Ptenfl tumors including bulk and single-cell RNA-sequencing, and multiplex tissue-imaging. Through comparison with human TNBC, we demonstrate that this genetic mouse model develops mammary tumors with differential survival and therapeutic responses that closely resemble the inter- and intra-tumoral and microenvironmental heterogeneity of human TNBC, providing a pre-clinical tool for assessing the spectrum of patient TNBC biology and drug response.